BiotechTube
AorticLab

AorticLab

Milan, Italy· Est.
aorticlab.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

AorticLab is a private, pre-revenue medical device innovator developing the FLOWer, a novel embolic protection device for TAVI procedures. The company aims to reduce stroke and other embolic risks by capturing debris with a 60 µm mesh deployed in the aortic arch, offering full-body protection. With a leadership team combining clinical, regulatory, and engineering expertise, and established distributor partnerships in Europe, AorticLab is positioned to address a significant unmet need in the growing structural heart market, though it faces competition and the inherent challenges of regulatory approval and market adoption.

CardiovascularStructural Heart Disease

Technology Platform

Embolic Protection Device (EPD) platform featuring a 60 µm mesh filter designed for placement in the aortic arch to capture debris during transcatheter procedures, aiming to provide full-body protection (cerebral, renal, peripheral).

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The rapid global expansion of TAVI procedures into lower-risk patient populations creates a large and growing addressable market for safety-improving devices.
Increasing clinical focus on post-procedural complications like stroke and renal injury underscores the need for effective embolic protection, potentially favoring a device with broader systemic claims.

Risk Factors

The company must prove the clinical superiority and economic value of its 'full-body' protection claim against established cerebral protection devices.
As a small, pre-revenue startup, AorticLab faces significant execution risks in regulatory approval, market access, and commercial scaling against larger, well-funded competitors.

Competitive Landscape

The TAVI embolic protection market includes established players like Boston Scientific (SENTINEL), Abbott, and newer entrants. Competition is intensifying, with differentiation based on ease of use, protection efficacy, and anatomical coverage. AorticLab's niche is its aortic arch positioning and claim of systemic protection, but it must demonstrate clear clinical benefits to overcome entrenched competitors.

More companies in Drug Delivery & Formulation →More companies in Italy →